Neuropsychiatric aspects of Parkinson’s disease: Recent advances

被引：13
|
作者：
Laura Marsh
Ariel Berk
机构：
[1] Johns Hopkins University School of Medicine,Division of Psychiatric Neuroimaging, Geriatric and Neuropsychiatry Programs, Department of Psychiatry and Behavioral Sciences
来源：
Current Psychiatry Reports | 2003年 / 5卷 / 1期
关键词：
Levodopa; Clozapine; Anxiety Disorder; Selegiline; Subthalamic Nucleus;
D O I：
10.1007/s11920-003-0012-6
中图分类号：
学科分类号：
摘要：
Psychiatric disturbances are a common feature of Parkinson’s disease (PD), which is a degenerative disorder defined by its characteristic movement abnormalities. Its management is optimal when PD is viewed as a neuropsychiatric disorder, because this encourages consideration of the motor deficits along with its psychiatric and cognitive aspects. This review addresses the diagnosis and treatment of the most common psychiatric disorders in PD, and provides an update of related clinical research, including studies on neurosurgical treatments.
引用
收藏
页码：68 / 76
页数：8
相关论文
共 50 条
  • [21] Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson's disease?
    Del Prete, Eleonora
    Schmitt, Emmanuelle
    Meoni, Sara
    Fraix, Valerie
    Castrioto, Anna
    Pelissier, Pierre
    Ceravolo, Roberto
    Moro, Elena
    NEUROLOGICAL SCIENCES, 2022, 43 (06) : 3641 - 3647
  • [22] Profile of Neuropsychiatric Symptoms in Parkinson's Disease: Surgical Candidates Compared to Controls
    Lamberti, Valerie M. J.
    Pereira, Bruno
    Lhommee, Eugenie
    Bichon, Amelie
    Schmitt, Emmanuelle
    Pelissier, Pierre
    Kistner, Andrea
    Fraix, Valerie
    Castrioto, Anna
    Esselink, Rianne A. J.
    Durif, Frank
    Krack, Paul
    JOURNAL OF PARKINSONS DISEASE, 2016, 6 (01) : 133 - 142
  • [23] Recent important trials of pharmacotherapy in Parkinson's disease
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 1025 - 1028
  • [24] Therapy in Parkinson’s disease: Some recent developments
    Amit Krishna De
    Resonance, 1999, 4 (5) : 78 - 87
  • [25] Neuropsychiatric features of Parkinson's disease in the era prior to the use of dopaminergic therapies
    Zhang, Chengyu
    Reeves, Suzanne
    David, Anthony S.
    Costello, Harry
    Rogers, Jonathan
    COGNITIVE NEUROPSYCHIATRY, 2023, 28 (04) : 243 - 252
  • [26] Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease
    Li, Jialin
    Ebrahimi, Anita Haj
    Ali, Afia B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [27] Advances in Stem Cells Transplantation for the Therapy of Parkinson's Disease
    Zeng, Xiansi
    Geng, Wenshuo
    Jia, Jinjing
    Wang, Zhanqi
    CURRENT STEM CELL RESEARCH & THERAPY, 2021, 16 (08) : 958 - 969
  • [28] Recent advances in using diffusion tensor imaging to study white matter alterations in Parkinson's disease: A mini review
    Shih, Yao-Chia
    Tseng, Wen-Yih Isaac
    Montaser-Kouhsari, Leila
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 14
  • [29] Fluctuations in Parkinson's disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
    Schmitt, Emmanuelle
    Debu, Bettina
    Castrioto, Ana
    Kistner, Andrea
    Fraix, Valerie
    Bouvard, Martine
    Moro, Elena
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [30] An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease
    Hatano, Taku
    Hattori, Nobutaka
    Kawanabe, Tadaaki
    Terayama, Yasuo
    Suzuki, Norihiro
    Iwasaki, Yasuo
    Fujioka, Toshiki
    JOURNAL OF NEURAL TRANSMISSION, 2014, 121 (03) : 275 - 281
12345